Neuralstem to Participate at The Young Jewish Professionals CEO Healthcare Symposium
February 08 2018 - 7:00AM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced that Richard Daly, Chairman and CEO of Neuralstem, will
participate in a panel discussion entitled, “From Research &
Development to Commercial Venture: Building a Successful Biotech
Company” at the Young Jewish Professionals CEO Healthcare Symposium
in New York, New York, on Tuesday, February 13, 2018 at 8:30am
ET.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical
company developing novel treatments for nervous system diseases of
high unmet medical need. The Company’s lead development candidate,
NSI-189, is a small molecule in clinical development for major
depressive disorder (MDD) and in preclinical development for
Angelman syndrome, irradiation-induced cognitive impairment, Type 1
and Type 2 diabetes, and stroke. NSI-566 is a stem cell therapy
being tested for treatment of paralysis in stroke, chronic spinal
cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS).
Neuralstem’s diversified portfolio of product candidates is based
on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward
Looking Information
This news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2016, and Form 10-Q for the three and nine
months ended September 30, 2017, filed with the Securities and
Exchange Commission (SEC), and in other reports filed with the SEC.
We do not assume any obligation to update any forward-looking
statements.
Contact:
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2023 to Apr 2024